Compounds > etofamide
Page last updated: 2024-12-06

etofamide

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Etofamide is a selective inhibitor of monoamine oxidase A (MAO-A) with antidepressant and anxiolytic effects. It was initially synthesized in the 1960s and studied for its potential therapeutic use in treating depression and anxiety disorders. Research has shown that etofamide effectively inhibits MAO-A, leading to an increase in the levels of neurotransmitters such as serotonin and norepinephrine, which are implicated in mood regulation. However, etofamide's clinical development was discontinued due to concerns about its potential side effects, including hepatotoxicity and interactions with other medications. Despite its limited clinical application, etofamide continues to be studied as a pharmacological tool to understand the role of MAO-A inhibition in mood disorders and as a potential lead compound for the development of novel antidepressants with improved safety profiles.'

etofamide: structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID65718
CHEMBL ID1788393
CHEBI ID135692
SCHEMBL ID1163863
MeSH IDM0055455

Synonyms (38)

Synonym
ethylchlordiphene
n-(2-ethoxyethyl)-n-(p-(p-nitrophenoxy)-benzyl)dichloracetamide
eticlordifene
2,2-dichloro-n-(2-ethoxyethyl)-n-(p-(p-nitrophenoxy)benzyl)acetamide
kitnosil
chlorophenoxamide ethyl ether
brn 2918322
etofamidum [inn-latin]
acetamide, 2,2-dichloro-n-(2-ethoxyethyl)-n-((4-(4-nitrophenoxy)phenyl)methyl)-
2,2-dichloro-n-(2-ethoxyethyl)-n-((p-nitrophenoxy)benzyl)-acetamide
acetamide, 2,2-dichloro-n-(2-ethoxyethyl)-n-(p-(p-nitrophenoxy)benzyl)-
etofamide
einecs 246-790-2
k-430
kitnos
etofamida [inn-spanish]
n-(2-etossietil)-n-(4-(4'-nitrofenossi)benzil)dicloroacetamide [italian]
etofamide [inn]
25287-60-9
D07355
kitnos (tn)
etofamide (inn)
CHEBI:135692
2,2-dichloro-n-(2-ethoxyethyl)-n-[[4-(4-nitrophenoxy)phenyl]methyl]acetamide
unii-03f36jh21u
n-(2-etossietil)-n-(4-(4'-nitrofenossi)benzil)dicloroacetamide
03f36jh21u ,
etofamida
etofamidum
CHEMBL1788393
etofamide [mart.]
etofamide [who-dd]
SCHEMBL1163863
DTXSID40179926
Q5404754
DB13258
EN300-19765938
2,2-dichloro-n-(2-ethoxyethyl)-n-{[4-(4-nitrophenoxy)phenyl]methyl}acetamide
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
aromatic etherAny ether in which the oxygen is attached to at least one aryl substituent.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Bioassays (1)

Assay IDTitleYearJournalArticle
AID1124509Antiamebic activity against Entamoeba criceti infected in hamster assessed as reduction of trophozoites in cecum administered intragastric gavage as four dose by microscopy1979Journal of medicinal chemistry, May, Volume: 22, Issue:5
1-(Dichloroacetyl)-1,2,3,4-tetrahydro-6-quinolinol esters. New potent antiamebic agents.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (7)

TimeframeStudies, This Drug (%)All Drugs %
pre-19903 (42.86)18.7374
1990's4 (57.14)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 27.90

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index27.90 (24.57)
Research Supply Index2.40 (2.92)
Research Growth Index4.51 (4.65)
Search Engine Demand Index31.58 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (27.90)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials2 (25.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies1 (12.50%)4.05%
Observational0 (0.00%)0.25%
Other5 (62.50%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
azomycin
azomycin: RN given refers to parent cpd with specified locant; structure		1.9910C-nitro compound;
imidazoles		antitubercular agent
4-nitroimidazole
5-nitroimidazole : A C-nitro compound that is imidazole bearing a nitro substituent at position 5.		1.9910C-nitro compound;
imidazoles
diloxanide furoate
diloxanide furoate: structure. diloxanide furoate : A carboxylic ester resulting from the formal condensation of the carboxy group of furan-2-carboxylic acid with the hydroxy group of 2,2-dichloro-N-(4-hydroxyphenyl)-N-methylacetamide. It is a drug used for the treatment of asymptomatic amebiasis.		1.9510carboxylic ester;
furans;
organochlorine compound;
tertiary carboxamide		antiamoebic agent;
prodrug
nimorazole
Nimorazole: An antitrichomonal agent which is effective either topically or orally and whose urinary metabolites are also trichomonicidal.		3.3611C-nitro compound;
imidazoles
ornidazole
Ornidazole: A nitroimidazole antiprotozoal agent used in ameba and trichomonas infections. It is partially plasma-bound and also has radiation-sensitizing action.. ornidazole : A C-nitro compound that is 5-nitroimidazole in which the hydrogens at positions 1 and 2 are replaced by 3-chloro-2-hydroxypropyl and methyl groups, respectively. It is used in the treatment of susceptible protozoal infections and for the treatment of anaerobic bacterial infections.		210C-nitro compound;
imidazoles;
organochlorine compound;
secondary alcohol		antiamoebic agent;
antibacterial drug;
antiinfective agent;
antiprotozoal drug;
antitrichomonal drug;
epitope
quinfamide
[no description available]		9.0531quinolines
paromomycin
Paromomycin: An aminoglycoside antibacterial and antiprotozoal agent produced by species of STREPTOMYCES.. paromomycin : An amino cyclitol glycoside that is the 1-O-(2-amino-2-deoxy-alpha-D-glucopyranoside) and the 3-O-(2,6-diamino-2,6-dideoxy-beta-L-idopyranosyl)-beta-D-ribofuranoside of 4,6-diamino-2,3-dihydroxycyclohexane (the 1R,2R,3S,4R,6S diastereoisomer). It is obtained from various Streptomyces species. A broad-spectrum antibiotic, it is used (generally as the sulfate salt) for the treatment of acute and chronic intestinal protozoal infections, but is not effective for extraintestinal protozoal infections. It is also used as a therapeutic against visceral leishmaniasis.		3.7721amino cyclitol glycoside;
aminoglycoside antibiotic		anthelminthic drug;
antibacterial drug;
antiparasitic agent;
antiprotozoal drug
ConditionIndicatedRelationship StrengthStudiesTrials
Amebiasis, Intestinal
[description not available]		03.7621
Entamoeba histolytica Infection
[description not available]		03.7721
Intestinal Diseases
Pathological processes in any segment of the INTESTINE from DUODENUM to RECTUM.		03.3611
Abscess, Amebic
[description not available]		01.9510
Amebiasis
Infection with any of various amebae. It is an asymptomatic carrier state in most individuals, but diseases ranging from chronic, mild diarrhea to fulminant dysentery may occur.		01.9510